One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Study protocol and baseline characteristics of Randomized trial for Evaluation in Secondary Prevention Efficacy of Combination Therapy–Statin and Eicosapentaenoic Acid: RESPECT-EPA, the combination of a randomized control trial and an observational biomarker study
Yuji Nishizaki, MD MPH PhD a , Katsumi Miyauchi, MD PhD a , Hiroshi Iwata, MD PhD a , Teruo Inoue, MD PhD b,c , Atsushi Hirayama, MD PhD d , Kazuo Kimura, MD PhD e , Yukio Ozaki, MD PhD f , Toyoaki Murohara, MD PhD g , Kenji Ueshima, MD PhD h , Yoshihiro Kuwabara, MD PhD i , Sachiko Tanaka-Mizuno, PhD j , Naotake Yanagisawa, PhD k , Tosiya Sato, PhD l , and Hiroyuki Daida, MD a,m Tokyo, Japan; Tochigi, Japan; Osaka, Japan; Yokohama, Japan; Aichi, Japan; Kyoto, Japan
doi : 10.1016/j.ahj.2022.11.008
Volume 257, March 2023, Pages 1-8
Percutaneous coronary intervention of native coronary artery versus saphenous vein graft in patients with prior coronary artery bypass graft surgery: Rationale and design of the multicenter, randomized PROCTOR trial
Ruben W. de Winter, MD a , Simon J. Walsh, MD, PhD b , Colm G. Hanratty, MD, PhD c , James C. Spratt, MD, PhD d , Ralf W. Sprengers, MD, PhD e , Jos W.R. Twisk, PhD f , Iris Vegting, Msc a , Stefan P. Schumacher, MD a , Michiel J. Bom, MD, PhD a , Roel Hoek, MD a , Niels J. Verouden, MD, PhD a , Ronak Delewi, MD, PhD a , Alexander Nap, MD, PhD a , and Paul Knaapen, MD, PhD a , on behalf of the PROCTOR Trial Research Group Amsterdam, the Netherlands; Belfast, United Kingdom; Dublin, Ireland
doi : 10.1016/j.ahj.2022.11.014
Volume 257, March 2023, Pages 20-29
Rationale and design of BROKEN-SWEDEHEART: a registry-based, randomized, parallel, open-label multicenter trial to test pharmacological treatments for broken heart (takotsubo) syndrome
Elmir Omerovic, MD PhD a , Stefan James, MD PhD b , David Erlinge, MD PhD c , Henrik Hagström, PhD d , Dimitrios Venetsanos, MD PhD e , Loghman Henareh, MD PhD e , Christina Ekenbäck, MD f , Joakim Alfredsson, MD PhD g , Kristina Hambreus, MD PhD h , and Björn Redfors, MD PhD a Gothenburg, Sweden; Uppsala, Sweden; Lund, Sweden; Stockholm, Sweden; Falun, Sweden
doi : 10.1016/j.ahj.2022.11.010
Volume 257, March 2023, Pages 33-40
International randomized trial on the effect of revascularization or optimal medical therapy of chronic total coronary occlusions with myocardial ischemia - ISCHEMIA-CTO trial – rationale and design
Truls Råmunddal, MD, PhD 1,# , Emil Nielsen Holck, MD 2,# , Salma Karim, MD 2 , Ashkan Eftekhari, MD PhD 3 , Javier Escaned, MD PhD 4 , Dan Ioanes, MD 1 , Simon Walsh, MD 5 , James Spratt, MD DMSc 6 , Karsten Veien, MD PhD 7 , Lisette Okkels Jensen, MD PhD DMSci 7 , Hans-Henrik Tilsted, MD PhD 8 , Christian Juhl Terkelsen, MD PhD 2 , Ole Havndrup, MD PhD 9 , Niels Thue Olsen, MD PhD 10 , Olli A. Kajander, MD PhD 11 , Benjamin Faurie, MD 12 , Peep Lanematt, MD PhD 13 , Lars Jakobsen, MD PhD 2 , and Evald Høj Christiansen, MD PhD
doi : 10.1016/j.ahj.2022.11.016
Volume 257, March 2023, Pages 41-50
The rationale, design, and methods of a trial to evaluate the efficacy and safety of oxygen therapy in patients with intermediate-risk acute pulmonary embolism
Diego Durán, MD a , Deisy Barrios, PhD a,b , Jorge Moisés, MD b,c , Ana Retegui, MD a , Carmen RodrÃguez, MD a , José L. Lobo, MD b,d , Raquel López-Reyes, MD b,e , Leyre Chasco, MD f , Luis Jara-Palomares, PhD b,g , Manuel Monreal, PhD b,h,i , Behnood Bikdeli, MD j,k,l , and David Jiménez, PhD a,b,m on behalf of the AIR investigators, Madrid, Spain; Madrid, Spain; Barcelona, Spain; Valencia, Spain; Bilbao, Spain; Barcelona, Spain; Boston, MA; New Haven, CT; New York, NY; Madrid, Spain
doi : 10.1016/j.ahj.2022.11.017
Volume 257, March 2023, Pages 62-68
Early treatment with a sodium-glucose co-transporter 2 inhibitor in high-risk patients with acute heart failure: Rationale for and design of the EMPA-AHF trial
Yu Horiuchi a,b,1 , Yuya Matsue b,1 , Kazutaka Nogi c , Ken Onitsuka d , Takahiro Okumura e , Masahiro Hoshino f , Tatsuhiro Shibata g , Daisuke Nitta h , Kazuki Yoshida i , Shuntaro Sato j , Kevin Damman k , Adriaan A. Voors k , and Takeshi Kitai l Tokyo, Japan; Nara, Japan; Fukuoka, Japan; Nagoya, Japan; Ibaraki, Japan; Nagasaki, Japan; Groningen, Netherlands; Osaka, Japan
doi : 10.1016/j.ahj.2022.12.005
Volume 257, March 2023, Pages 85-92
Rationale and design of the Effects of intensive Systolic blood Pressure lowering treatment in reducing RIsk of vascular evenTs (ESPRIT): A multicenter open-label randomized controlled trial
Jiamin Liu, MD a,# , Bin Wang, PhD, MD a,# , Yan Li, MD a , Xiaofang Yan, MD a , Jinzhuo Ge, BM a , and Jing Li, PhD, MD a,b Beijing, China; Henan, China
doi : 10.1016/j.ahj.2022.12.003
Volume 257, March 2023, Pages 93-102
Evaluation of Huawei smart wearables for detection of atrial fibrillation in patients following ischemic stroke: The Liverpool-Huawei stroke study
Stephanie L. Harrison, PhD a,b , Benjamin J.R. Buckley, PhD a,b,c , Yalin Zheng, PhD a,d , Andrew Hill, MBChB, MSc a,e , Thant Hlaing, MBChB a,f , Ruth Davies, MBChB g , Yutao Guo, PhD a,h , Deirdre A. Lane, PhD a,b,i,# , and Gregory Y.H. Lip, MD a,b,c,i,# , on behalf of the Liverpool-Huawei Stroke Study Investigatorsj,∗ Liverpool, United Kingdom; Merseyside, United Kingdom; Beijing, China; Aalborg, Denmark; Thessaly, Greece; Riyadh, Saudi Arabia
doi : 10.1016/j.ahj.2022.12.004
Volume 257, March 2023, Pages 103-110
Pragmatic trial of messaging to providers about treatment of acute heart failure: The PROMPT-AHF trial
Lama Ghazi, MD, PhD a,# , Kyle O’Connor, MS a,# , Yu Yamamoto, MS a , Michael Fuery, MD b , Sounok Sen, MD b , Marc Samsky, MD b , Ralph J. Riello III, PharmD a , Joanna Huang, PharmD d , Temitope Olufade, PhD, MPH d , James McDermott, PhD d , Silvio E. Inzucchi, MD c , Eric J. Velazquez, MD b , Francis Perry Wilson, MD, MSCE a , Nihar R. Desai, MD, MPH a,b , and Tariq Ahmad, MD, MPH a,b Wilmington, DE
doi : 10.1016/j.ahj.2022.12.002
Volume 257, March 2023, Pages 111-119
Rationale and design for the myocardial ischemia and transfusion (MINT) randomized clinical trial
Jeffrey L. Carson, MD a,1 , Maria Mori Brooks, PhD b,1 , Bernard R. Chaitman, MD c , John H. Alexander, MD MHS d , Shaun G. Goodman, MD MSc e,f , Marnie Bertolet, PhD b , J. Dawn Abbott, MD g , Howard A. Cooper, MD h , Sunil V. Rao, MD i,j , Darrell J. Triulzi, MD k , Dean A. Fergusson, PhD l , William J. Kostis, PhD MD a , Helaine Noveck, MPH a , Tabassome Simon, MD PhD m , Philippe Gabriel Steg, MD n , Andrew P. DeFilippis, MD o , Andrew M. Goldsweig, MD MS p , Renato D. Lopes, MD q,d , Harvey White, DSc r , Caroline Alsweiler, PhD r , Erin Morton, PhD s , and Paul C. Hébert, MD MHSc t , on behalf of the MINT Investigators∗ New Brunswick, NJ; Pittsburgh, PA; St Louis, MO; Durham, NC; Alberta, Canada; Providence, RI; Valhalla, NY; New York, NY; Ontario, Canada; Paris, France; Nashville, TN; Omaha, NE; Auckland, New Zealand; Adelaide, Australia; Quebec, Canada
doi : 10.1016/j.ahj.2022.11.015
Volume 257, March 2023, Pages 120-129
Impact of coronary disease patterns, anatomical factors, micro-vascular disease and non-coronary cardiac factors on invasive coronary physiology
Avedis Ekmejian, MBBS, MSc a,b,c , Usaid Allahwala, BSc (Med) (Hons), MBBS (Hons I), PhD a,b,c , Michael Ward, MBBS, PhD a,b,c , and Ravinay Bhindi, MBBS, MSc, PhD a,b,c St Leonards, Australia
doi : 10.1016/j.ahj.2022.12.006
Volume 257, March 2023, Pages 51-61
Invasive coronary physiology has been applied by interventional cardiologists to guide the management of coronary artery disease (CAD), with well-defined thresholds applied to determine whether CAD should be managed with optimal medical therapy (OMT) alone or OMT and percutaneous coronary intervention (PCI).
Incidence of sudden cardiac arrest and sudden cardiac death after unstable angina pectoris and myocardial infarction
Minna Koivunen, MD a , Juho Tynkkynen, MD, PhD b , Niku Oksala, MD, PhD a,c,d , Markku Eskola, MD, PhD e , and Jussi Hernesniemi, MD, PhD a,d,e Tampere, Finland
doi : 10.1016/j.ahj.2022.11.009
Volume 257, March 2023, Pages 9-19
Long-term antithrombotic therapy after coronary artery bypass grafting in patients with preoperative atrial fibrillation. A nationwide observational study from the SWEDEHEART registry
Mikolaj Skibniewski, MD a , Dimitrios Venetsanos, MD, PhD b , Anders Ahlsson, MD, PhD c , Gorav Batra, MD, PhD d , Örjan Friberg, MD, PhD e , Robin Hofmann, MD, PhD f , Magnus Janzon, MD, PhD a , Lars O Karlsson, MD, PhD a , Sofia Sederholm Lawesson, MD, PhD a , Susanne J. Nielsen, RN, PhD g,h , Anders Jeppsson, MD, PhD g,h , and Joakim Alfredsson, MD, PhD a Linkoping, Sweden; Stockholm, Sweden; Uppsala, Sweden; Gothenburg, Sweden
doi : 10.1016/j.ahj.2022.12.001
Volume 257, March 2023, Pages 69-77
Predicted lean body mass, fat mass, and heart failure in patients with type 2 diabetes mellitus
Xianming Tang, MD a,b , Yanling Zhu, MD c , and Zhenhua Xing, MD a,b Changsha, China; Foshan Sanshui, China
doi : 10.1016/j.ahj.2022.12.008
Volume 257, March 2023, Pages 78-84
Men who live alone have worse anticoagulation control: A Danish registry study
Anders Nissen Bonde, MD, PhD 1 , Jenny Bjerre, MD 1 , Marco Proietti, MD PhD 2,3 , Gregory YH Lip, MD 4,5 , Gunnar Gislason, MD PhD 1 , and Mark A Hlatky, MD 6 Gentofte; Milan; Liverpool; Aalborg; Stanford, CA
doi : 10.1016/j.ahj.2022.11.006
Volume 257, March 2023, Pages 30-32
